Roche reports slightly better sales than predicted in Q1

In Q1 2021, pharmaceutical company Roche has had better sales than predicted, especially in terms of diagnostics and hemophilia drug Hemlibra.

Photo: Michael Buholzer/Reuters/Ritzau Scanpix

Swiss pharmaceutical giant Roche has had better sales than the company forecast in the first three months of the year, as diagnostics equipment and the hemophilia medicine Hemlibra in particular have sold surprisingly well, according to the firm's Q1 report.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Extra data boosts Lundbeck's agitation case

Pharmaceutical firm Lundbeck has presented positive new data at a US conference as it seeks approval for its candidate Rexulti as a treatment for agitation in Alzheimer’s patients.

Further reading

Related articles

Latest news

See all jobs